The potential neuroprotective effects of the combined treatment using PPARα and PPARγ agonists should also be further assessed in AD and PD in the framework of preclinical and clinical studies, emphasizing on the determination of the optimal conditions (dosage and time) in order to avoid the potentially important side effects of the dual treatment. The gene discussed is PPARG; the disease is Alzheimer disease.